Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рамиприл – ингибитор ангиотензинпревращающего фермента с широким спектром терапевтического действия
Рамиприл – ингибитор ангиотензинпревращающего фермента с широким спектром терапевтического действия
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ключевые слова: артериальная гипертензия, ИАПФ, рамиприл
________________________________________________
Полный текст
Список литературы
1. Сидоренко Б.А., Преображенский Д.В. Клиническое применение ингибиторов ангиотензин-превращающего фермента. М.: ЛИА "Пресид", 1998.
2. Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М.: ЗАО "Информатик", 1999.
3. Opie LH. Angiotensin converting enzyme inhibitors. 2 ed N.Y.: Wiley-Liss, 1994.
4. Opie LH. Angiotensin converting enzyme inhibitors. 3 ed N.Y.: Wiley-Liss, 1999.
5. Opie LH. Drugs for the heart. 4th ed Philadelphia, 1995.
6. Gohlke P, Unger T. Ramipril Cardiovascular drug therapy. Ed. F. Messerli 2th ed Philadelphia, 1996: 755–75.
7. Ball SG, Roberson JIS. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59: 23D–7D.
8. Todd PA, Benfield P. Ramipril: a review of its pharmacologic properties and therapeutic efficacy in cardiovascular disoreders. Drugs, 1990; 39: 110–35.
9. Smith WHT, Ball SG. Ramipril. Int. J. Clin. Practice, 2000; 54: 255–60.
10. Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Ингибиторы ангиотензин-превращающего фермента – М.: Литтерра, 2007.
11. Ивлева А.Я. Клиническое применение ингибиторов ангиотензинпревращающего фермента и антагонистов ангиотензина II. М.: Миклош, 1998.
12. Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. ИАПФ и АТ1-ангиотензиновые блокаторы в клинической практике. Часть вторая. М.: ЗАО "Презид-Альянс", 2004.
13. Zannad F, Matzinger A, Larche J. Trough/peak rations of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertension 1996; 9: 633–43.
14. Eichstadt HW, Felix R, Langer M et al. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D–103D.
15. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertension 1995; 13: 1225–334.
16. Psaty B, Smith NL, Siscovick DS et al Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis. JAMA 1997; 277: 739–45.
17. Pahor M, Psaty BM, Alderman MA et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949–54.
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regims on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–35.
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000; 342: 145–53.
20. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821–8.
21. Hall AS, Murray GD, Ball SG et al. Follow-up study of patients randomly allocated ramipril of placebo foe heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1999; 349: 1493–7.
22. The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63.
23. Ruggenenti P, Perna A, Gherardi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Lancet 1999; 354: 359–64.
2. Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М.: ЗАО "Информатик", 1999.
3. Opie LH. Angiotensin converting enzyme inhibitors. 2 ed N.Y.: Wiley-Liss, 1994.
4. Opie LH. Angiotensin converting enzyme inhibitors. 3 ed N.Y.: Wiley-Liss, 1999.
5. Opie LH. Drugs for the heart. 4th ed Philadelphia, 1995.
6. Gohlke P, Unger T. Ramipril Cardiovascular drug therapy. Ed. F. Messerli 2th ed Philadelphia, 1996: 755–75.
7. Ball SG, Roberson JIS. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59: 23D–7D.
8. Todd PA, Benfield P. Ramipril: a review of its pharmacologic properties and therapeutic efficacy in cardiovascular disoreders. Drugs, 1990; 39: 110–35.
9. Smith WHT, Ball SG. Ramipril. Int. J. Clin. Practice, 2000; 54: 255–60.
10. Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Ингибиторы ангиотензин-превращающего фермента – М.: Литтерра, 2007.
11. Ивлева А.Я. Клиническое применение ингибиторов ангиотензинпревращающего фермента и антагонистов ангиотензина II. М.: Миклош, 1998.
12. Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. ИАПФ и АТ1-ангиотензиновые блокаторы в клинической практике. Часть вторая. М.: ЗАО "Презид-Альянс", 2004.
13. Zannad F, Matzinger A, Larche J. Trough/peak rations of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertension 1996; 9: 633–43.
14. Eichstadt HW, Felix R, Langer M et al. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D–103D.
15. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertension 1995; 13: 1225–334.
16. Psaty B, Smith NL, Siscovick DS et al Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis. JAMA 1997; 277: 739–45.
17. Pahor M, Psaty BM, Alderman MA et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949–54.
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regims on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–35.
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000; 342: 145–53.
20. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821–8.
21. Hall AS, Murray GD, Ball SG et al. Follow-up study of patients randomly allocated ramipril of placebo foe heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1999; 349: 1493–7.
22. The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63.
23. Ruggenenti P, Perna A, Gherardi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Lancet 1999; 354: 359–64.
Авторы
Д.В.Преображенский*, И.Д.Вышинская
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова
*d_preobra@mail.ru
*d_preobra@mail.ru
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова
*d_preobra@mail.ru
________________________________________________
*d_preobra@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.